Despite the superior cardiorenal benefits of sodium/glucose cotransporter-2 inhibitors (SGLT-2i) and GLP-1RAs [75, 76], DPP-4i remained a common choice among these three classes of anti-diabetic agents, with more patients using DPP-4i than the other two [77]
Dietary supplementation with a low dose of (-)-epigallocatechin-3-gallate reduces pro-inflammatory responses in peripheral leukocytes of non-obese type 2 diabetic GK rats
These can include: Hypersensitivity or allergic reactions Nausea, vomiting, or diarrhea Headaches or dizziness Joint pain or stiffness A flushing sensation after injection It is important to note that these risks are rare and usually mild
Mochi Health provides 1-on-1 provider support from licensed physicians who specialize in obesity medicine, ensuring youre supported every step of the way
Post-Injection Care You may experience a mild tingling or warmth at the injection site, but side effects are rare